Answers are grounded in this paper and cite their sources.
Dear Editor, In the UK, recommended noninvasive methods of detecting liver fibrosis differ between the clinical practice of hepatologists and dermatologists. A range of screening tools exist, including the Fibrosis (Fib)‐4 index, Enhanced Liver Fibrosis score and Fibroscan.1, 2 As an indirect marker for fibrosis, procollagen III N‐terminal peptide (P3NP) is still in widespread use in dermatology but less so in other medical specialties.2, 3 In addition, the recommended frequency for assessing fibrosis differs, with hepatologists measuring for progression to liver fibrosis much less frequently than dermatologists.1, 3 Clinically, significant liver fibrosis is thought to be a relatively slow process that takes years to develop and progress.4, 5 In a systematic review and meta‐analysis of paired liver biopsy studies, Singh et al.6 demonstrated that nonalcoholic fatty liver disease (NAFLD) at fibrosis stage 0 (no fibrosis) took a mean of 14.3 years to progress by one stage of fibrosis, and nonalcoholic steatohepatitis took 7.1 years. The author identified two subsets of patients, which they termed ‘rapid’ and ‘slow’ progressors; most patients were slow progressors, and the rapid progressors, who had progressed from stage 0 to stage 3–4 (severe fibrosis and cirrhosis) at the follow‐up liver biopsy did so over an average of 5.9 years.6
No takes yet. Share an insight, caveat, or question.
Raahimi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: